Company news
Pulmatrix, Inc. news in 2019
Pulmatrix, Inc.'s news releases, calls and decks from 2019, newest first.
Pulmatrix appoints Life Sciences Executive Rick Batycky to the Board of Directors
November 3, 2019
Pulmatrix Reports Q3 2019 Results
October 31, 2019
Pulmatrix and Cipla Announce First Patient Dosed in Phase 2 Trial Evaluating Pulmazole for Treatment of Allergic Bronchopulmonary Aspergillosis in Patients with Asthma
September 17, 2019
Pulmatrix Receives US Patent Covering iSPERSE(TM) Formulations for Pulmazole Program
August 18, 2019
Pulmatrix Reports Q2 2019 Results
August 4, 2019
Pulmatrix Activates Sites for Pulmazole Phase 2 Clinical Study
July 8, 2019
Pulmatrix Reports Q1 2019 Results
May 14, 2019
Pulmatrix and Cipla Technologies LLC enter into Definitive Agreement for the Development and Commercialization of Pulmazole(TM)
April 14, 2019
Pulmatrix, Inc. Announces Closing of $16.6 Million Upsized Public Offering
April 7, 2019
Pulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC for the Development and Commercialization of Pulmazole
March 31, 2019
Decks in 2019
- Investor Presentation (November 2019)
Investor deck · 33 slides · Nov 19, 2019
- Investor Presentation (August 2019)
Investor deck · 33 slides · Aug 22, 2019